Recent Articles

Remedy Robotics Raises $62M in Series B Funding Led by DCVC

Nov 17, 2026 | By Devin Jacobs

Remedy Robotics Raises $62M in Series B Funding Led by DCVC

SUMMARY

  • Remedy Robotics raised $62 million in Series B funding.
  • The funding will support its growth and clinical trials.
  • Remedy Robotics develops surgical robots.

Remedy Robotics, a San Francisco, CA-based healthcare and physical AI company developing robotic systems for cardiovascular and endovascular intervention, has raised $62 million in a Series B funding round.

The round was led by DCVC with participation from UC Investments, Skip Capital, Hostplus, Build Collective by Tony Fadell, Blackbird, Divergent Capital, and KdT Ventures.

The company plans to use the funding to advance clinical trials, move closer to FDA approval for neurovascular procedures, deploy its N1 robotic systems across clinical partner sites, and further develop its AI and autonomous capabilities.

What is Remedy Robotics?

Remedy Robotics develops AI powered robotic systems designed to perform endovascular procedures, which involve treating blood vessels from inside the body.

Read More:Microsoft Pivots to AI Agents as Azure Hits $100B, Though Cash Flow Dips

Its main product, the N1 System, combines robotics, machine learning, and computer vision to support procedures involving the brain, heart, and peripheral blood vessels.

The system can analyse medical images before a procedure, simulate cases in advance, and provide real-time 3D-to-2D image alignment. It is designed to support procedures performed on-site, remotely, or through autonomous functions.

The technology aims to improve access to specialised cardiovascular care, particularly in areas where experienced specialists, and advanced treatment facilities are limited.

About Remedy Robotics

How Much Funding Has Remedy Robotics Raised?

Remedy Robotics has raised $62 million in its Series B funding round. The company has not disclosed its total funding raised across previous rounds.

Who Invested in Remedy Robotics’ Series B?

The $62 million Series B round was led by DCVC.

Other participating investors included:

  • UC Investments
  • Skip Capital
  • Hostplus
  • Build Collective by Tony Fadell
  • Blackbird
  • Divergent Capital
  • KdT Ventures

Why the Funding Matters

Remedy Robotics will use the new capital to accelerate a planned pivotal clinical trial in partnership with the University of California.

The funding will also support the company's efforts to advance the N1 System towards FDA approval for neurovascular procedures. Remedy plans to deploy prototype N1 Systems across its clinical partner network and continue developing its AI capabilities and autonomous functions.

These developments are intended to support the use of robotic technology in more cardiovascular and endovascular procedures.

Remedy Robotics funding

Who founded Remedy Robotics?

Remedy Robotics was founded in 2021 by David Bell and Jake Sganga. The company is headquartered in San Francisco, California.

It focuses on developing robotic systems and software for on-site, remote, and autonomous medical interventions.

"Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals. For these time-critical conditions, that's devastating. Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common," said Dr. David Bell, CEO and Co-founder of Remedy Robotics.

Market and Business Growth

Remedy Robotics works with more than 100 hospitals worldwide. The company is among a group of physical AI businesses developing robotic technology for use in real clinical settings.

In October 2025, Remedy announced that it had completed the worlds first remote neurointerventional procedures using its N1 System.

The company also holds 48 patents covering its platform, including patents related to applying machine learning to surgical robotics. Its clinical and research work has been published in peer-reviewed journals, including Interventional Neuroradiology, and the American Journal of Neuroradiology.

What Happens Next?

Remedy Robotics plans to advance its pivotal clinical trial with the University of California, and continue working towards FDA approval for neurovascular intervention.

The company will also deploy prototype N1 Systems across its clinical partner network and improve the platforms AI and autonomous capabilities. These steps will support its plans to expand the use of robotic systems in specialised cardiovascular care.

Read More:858 Therapeutics Appoints Srini Ramanathan as Chief Executive Officer

Recommended Stories for You